On the stock market since 2015, it operates in the world of health and science. It has 1,000 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (5% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 30% below its peak. The market has trimmed its expectations for the company.
The company sells $901M a year; the problem isn’t sales — it’s costs running above that number.
There is $893M in the vault; even if every debt were paid off, $616M would remain.
The average analyst price target is $50.00 — 129% above today’s price.
A loss of $53M against $901M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, INVVY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: INVVY has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.